Navigation Links
Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
Date:5/22/2012

LEXINGTON, Mass., May 22, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company was awarded U.S. Patent 8,182,818, entitled "Methods of Using Anti-TNF Antibodies for Treating Radiation Damage to the Digestive Tract."

This patent provides broad coverage for using topically administered anti-TNF antibodies to treat radiation induced damage to the digestive tract.  Importantly, the patent specifically covers treatment of radiation induced mucositis, which is a common side effect of radiation therapy for cancer that often limits the effective radiation dose a patient can tolerate.  Avaxia has active research and development programs for its oral antibody AVX-470 for use in gastrointestinal acute radiation syndrome (GI-ARS) and mucositis. 

"This new patent emphasizes the innovative nature and broad applicability of our AVX Oral Antibody technology platform," stated Barbara Fox, PhD, CEO of Avaxia.  "For many cancer patients, the side effect of mucositis becomes intolerable, which causes terrible discomfort and may limit the dose of radiation that the patient receives to fight the disease.  Also, effective treatments for radiation damage are an important need for responding to potential terrorist attacks involving radioactive substances. Much of the morbidity and mortality associated with total body irradiation is due to damage to the GI tract. We are actively working to prove that AVX-470 can reduce that damage."

Avaxia has a $2.9 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop its oral anti-TNF antibody, AVX-470, for GI ARS. The work under this current contract explores the potential for the antibody to be further developed into a medical countermeasure to mitigate gastrointestinal damage from radiation exposure.

About Avaxia Biologics, Inc.: Avaxia is developing orally administered antibody therapeutics that act locally within the gastrointestinal (GI) tract.  Antibodies are widely used as therapeutics, with nearly $50 billion in annual sales worldwide.  Ordinary antibodies are not administered orally because they are destroyed in the GI tract.  In contrast, Avaxia has developed proprietary antibodies that are stable in the GI tract.  AVX Oral Antibodies make diseases with targets in the GI tract accessible to antibody therapeutics for the first time.  Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes, and obesity. 


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
2. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
3. Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
4. Avaxia Biologics Barbara Fox Named one of Mass High Techs Women to Watch in 2012
5. Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease
6. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
7. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
8. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
9. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
10. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
11. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
Breaking Medicine News(10 mins):